Featured Topics
Lead story
Other featured articles
-
Biosimilars Drug Market Isn’t Broken After All, USC Schaeffer Study Finds
Researchers looked at cancer therapy trastuzumab (Herceptin) and found biosimilars bring competition to the market, with prices declining by more than half for some versions.
Posted in -
Four Ways to Make Drug Price Negotiations Work for EveryoneÂ
The IRA will be measured not just by how much it can lower prices, but also by whether it continues to encourage drug makers to invest in new treatments.
Posted in -
Schaeffer Research Director Testifies at Congressional Hearing on Biomedical Innovation and Patient Access
Darius Lakdawalla was part of a panel of experts called upon by the U.S. House Ways and Means Subcommittee on Health.
Posted in -
Benefits of Medicare Coverage for Weight Loss Drugs
The cumulative social benefits from Medicare coverage for new obesity treatments over the next 10 years would reach almost $1 trillion, or roughly $100 billion per year.
Posted in
The Leonard D. Schaeffer Center for Health Policy & Economics, one of the nation’s premier policy centers, measurably improves value in health through evidence-based policy solutions, research excellence, and private- and public-sector engagement.
about
Our Policy Areas
From aging to drug pricing to health disparities, Schaeffer Center experts are advancing research to inform policy. Learn about the areas we work in.
Learn MoreWork & Study at USC
The Schaeffer Center develops innovators for positions in higher education, research, government and healthcare through degree programs and postgraduate opportunities.
Learn More